Routine blood donation testing data and demographics were extracted from the data warehouse of a large network of U.S. blood centers.
In the absence of pathogen inactivation treatment, a major advantage of using autologous platelet gel is avoiding the ethical and legal concerns of exposing the patient to the viral risks of allogeneic products [ 30], especially in countries with high infectious rates and limited donor screening and donation testing [ 31].
And if pre-donation testing revealed that one of them had the disorder, that brother might never be able to get health insurance.
However, the cost of screening donations is proportional to the number of donations tested, in addition to the resources expended investigating false alarms.
A study performed in asymptomatic blood donors from Puerto Rico during the inter-epidemic year 2005 reported that 0.7% (12 out of 16,521) blood donations tested positive for DENV RNA.
aIf one assumes 13.9 million annual blood donations tested, an average of one bioterror attack per year that infects 1,000 persons with a noncontagious agent, and a 1-month response and recovery period during which infected donations continue to arrive.
Another study conducted among blood donors during the epidemic year of 2007 found that 29 out of 15,350 donations tested positive for DENV RNA using an assay that detects all four DENV types but does not discriminate between DENV types.
In addition, the costs of screening apply to all blood donations tested: even if the cost of screening were as low as an incremental $10 per test, screening all blood donations in the United States to detect a bioterror attack would cost an additional $139 million per year at current donation rates.
Each retained sample tested negative for pathogens on all required donation screening tests and was also negative for investigational dengue virus (DENV, types 1 4) RNA by TMA (8 ).
The viral risks associated with blood transfusions, already reduced by extensive donation screening tests, are greatly minimized during the haemoglobin therapeutic manufacturing process by rigorous viral-inactivation procedures.
